Clarkston recently partnered with a biotech company that discovers, develops, and manufactures breakthrough therapeutics targeting rare disease populations, ultimately improving the personalization of the patient experience and using a digital approach to pharma.
Founded nearly 20 years ago, the client is the first to commercialize a groundbreaking gene therapy in the rare disease space. In 2015, the client selected Clarkston as a strategic partner to help enable the client’s 2020 Strategy – the transition from a late-stage clinical development company to a multi-product commercial company. Patient-centric in all they do, a personalized digital experience for its patients and healthcare professionals was a key goal for the client. The client set out to develop a portal that would introduce visitors to their designated case manager, who would guide them through the enrollment process and provide targeted materials and resources. The portal would serve as a one-stop shop for paper, digital, or email enrollment and help patients begin therapy.
Personal, user-friendly, and targeted to meet specific patient and healthcare professional needs, the site would serve as the entry point for the entire patient journey. Behind the scenes, the solution would integrate with the patient services cloud tool to manage all case manager and patient engagement, benefits review, and enrollment of patients on drug. Clarkston Consulting partnered with the client to manage the design, development, and extensive launch planning to ensure the patient-first approach was in place to enroll and support patients on day one of approval.